Published in Vaccine Weekly, June 4th, 2008
Dr. Armen will provide an overview of the company and its priority development programs, including Oncophage(R) (vitespen) therapeutic cancer vaccine; QS-21(TM) vaccine adjuvant; AG-707 therapeutic vaccine for genital herpes infection; and Aroplatin(TM) platinum agent for cancers.
The audio portion of the presentation and presentation slides will be webcast live and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.